A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.
Liu WD, Feng PH, Cheng CY, Chou CL, Lee CH, Lu MC, Liu PY, Lee MH, Liao CH, Chen MC, Chen CP, Hsu SF, Tzeng YT, Lin YC, Ou TY, Qin A, Tsai CY, Shih WJ, Lee KY, Sheng WH.
Liu WD, et al. Among authors: chen mc.
Infect Dis Ther. 2024 May 21. doi: 10.1007/s40121-024-00992-5. Online ahead of print.
Infect Dis Ther. 2024.
PMID: 38771550